Redmile Group LLC boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 87.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,599,700 shares of the biopharmaceutical company’s stock after purchasing an additional 745,000 shares during the quarter. Bristol-Myers Squibb comprises about 2.2% of Redmile Group LLC’s portfolio, making the stock its 16th biggest position. Redmile Group LLC’s holdings in Bristol-Myers Squibb were worth $76,322,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Legal & General Group Plc increased its holdings in Bristol-Myers Squibb by 5.9% in the fourth quarter. Legal & General Group Plc now owns 8,568,445 shares of the biopharmaceutical company’s stock valued at $445,300,000 after buying an additional 474,820 shares during the last quarter. Chescapmanager LLC grew its holdings in shares of Bristol-Myers Squibb by 22.1% during the fourth quarter. Chescapmanager LLC now owns 361,755 shares of the biopharmaceutical company’s stock worth $18,804,000 after purchasing an additional 65,367 shares during the last quarter. Perella Weinberg Partners Capital Management LP grew its holdings in shares of Bristol-Myers Squibb by 10.9% during the first quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 1,905 shares during the last quarter. Stephens Inc. AR grew its holdings in shares of Bristol-Myers Squibb by 30.7% during the first quarter. Stephens Inc. AR now owns 216,532 shares of the biopharmaceutical company’s stock worth $10,331,000 after purchasing an additional 50,798 shares during the last quarter. Finally, Phocas Financial Corp. purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $73,000. Institutional investors own 77.54% of the company’s stock.
In related news, insider Karen Murphy Santiago sold 3,065 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the completion of the sale, the insider now owns 3,066 shares of the company’s stock, valued at approximately $145,818.96. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Theodore R. Samuels II acquired 5,000 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were acquired at an average cost of $47.29 per share, with a total value of $236,450.00. Following the transaction, the director now owns 27,000 shares in the company, valued at $1,276,830. The disclosure for this purchase can be found here. Corporate insiders own 0.12% of the company’s stock.
Shares of Bristol-Myers Squibb stock opened at $47.56 on Monday. The stock has a market capitalization of $77.79 billion, a PE ratio of 11.95, a P/E/G ratio of 2.22 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.79 and a debt-to-equity ratio of 0.37. Bristol-Myers Squibb Co has a 1 year low of $44.30 and a 1 year high of $63.69.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.01. The business had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The company’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.94 EPS. Sell-side analysts forecast that Bristol-Myers Squibb Co will post 4.18 earnings per share for the current year.
A number of equities analysts recently issued reports on BMY shares. BMO Capital Markets reissued a “buy” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, February 19th. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 price target on the stock in a report on Tuesday, March 5th. Goldman Sachs Group started coverage on Bristol-Myers Squibb in a report on Tuesday, May 28th. They set a “buy” rating and a $54.00 price target on the stock. Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price target on the stock. in a report on Monday, May 20th. Finally, Bank of America lowered their price target on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a report on Tuesday, February 19th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $56.34.
WARNING: “Redmile Group LLC Grows Holdings in Bristol-Myers Squibb Co (NYSE:BMY)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2019/06/17/redmile-group-llc-grows-holdings-in-bristol-myers-squibb-co-nysebmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
See Also: Swap
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.